SharePrinter-friendly versionSend by emailA TitleA TitleA Title A A A Amy E. L. Schoenhard TabsetOverviewBar & Court Admission Bar & Court Admissions District of Columbia Bar Virginia Bar US Court of Appeals, District of Columbia CircuitUS Court of Appeals, Federal CircuitUS Court of Appeals, 4th Circuit Education Duke University School of Law, JD, 2003 Wake Forest University, BS, 2000 Amy E. L. SchoenhardPartnerWashington, DC T 202.857.6397 E amy.schoenhard@arentfox.com Download vCard Amy Schoenhard is a partner at Arent Fox and a registered US patent attorney. Amy specializes in the biotechnology, chemical, and pharmaceutical arts. Her practice consists primarily of patent litigation, patent prosecution, and opinion work. Client Work Amy’s litigation experience includes cases in the technical fields of biotechnology, pharmaceuticals, medical devices, herbal supplements, and fiber optic cable installation. Her patent prosecution experience includes drafting and prosecuting patent applications on behalf of US and international clients, as well as validity and infringement searches, studies, and opinions. Professional Activities Amy is a member of the American Bar Association and the American Intellectual Property Law Association (AIPLA). Amy is also an active member of the firm's Prescription Drugs and Vaccines Group, an interdisciplinary team of attorneys focused on the patent, regulatory, health care and corporate issues unique to brand-name and generic pharmaceutical industries. Amy also serves as an intake volunteer at the Legal Aid Society for the District of Columbia. Publications, Presentations, and Recognitions An active writer, Amy has been published numerous times in various legal and scientific journals. Her publications include the following: “Behavioral Effects of Ivermectin in Mice,” Laboratory Animal Science; 1999 (Volume 49, No.3, p. 288-296), co-written with J.A. Davis, R. Paylor, M.P. McDonald, M. Libbey, and J.N. Crawley “Egregious Error Or Admirable Advance: The Memorandum of Understanding That Enables Federally Funded Basic Human Embryonic Stem Cell Research,” Duke Law & Technology Review 2001 (Vol. 37) Patentability and Maximum Protection of Intellectual Property in Proteomics and Genomics, 4 Pharmacogenomics 1; 2003, revised for a legal audience and reprinted at 22 Biotechnology L. Rep. 264 ; 2003, co-written with R.J. Warburg, A. Wellman, and T. Buck “Defenses to Patent Infringement Under 35 USC § 271(g) Unavailable In ITC Exclusion Cases,” July 3, 2004, co-written with Richard J. Berman “Equivalents Presumptively Unavailable for Patent Claims Rewritten in Independent Form”; July 3, 2004, co-written with George Oram “The Level of Disclosure Necessary for Patent Protection of Genetic Innovations,” Nature Biotechnology; October 2004 (Vol. 22 No. 10), co-written with Richard J. Berman “Patent Re-examination Procedure as a Litigation Strategy,” Building and Enforcing Intellectual Property Value 2005; December 2004 (p. 222-225), co-written with Barry P. Golob Newsroom Date Type Title 12 / 28 / 2012 Press Release Arent Fox Announces 2013 Promotions to Partner and Counsel 7 / 18 / 2012 Event Arent Fox's Janine Carlan and Amy Schoenhard to Speak at The Food and Drug Law Institute's "Intellectual Property Throughout the Drug Development Lifecycle: Opportunities and Challenges" Conference 7 / 3 / 2004 Alert Defenses to Patent Infringement Under 35 USC § 271(g) Unavailable In ITC Exclusion Cases
